NeuroBo Pharmaceuticals (NRBO)
NASDAQ:NRBO
US Market
Holding NRBO?
Track your performance easily

NeuroBo Pharmaceuticals (NRBO) Income Statement

322 Followers

NeuroBo Pharmaceuticals Income Statement

Last quarter (Q2 2024), NeuroBo Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, NeuroBo Pharmaceuticals's net income was $-10.05M. See NeuroBo Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 24.66M$ 15.89M$ 19.63M$ 15.30M$ 29.72M$ 20.18M
Operating Income
$ -24.66M$ -15.89M$ -19.63M$ -15.30M$ -29.72M$ -20.18M
Net Non Operating Interest Income Expense
$ 563.00K$ 461.00K$ -2.19M-$ 39.00K$ -22.00K
Other Income Expense
$ -2.78M$ -2.96M$ -7.85M$ -17.72M$ -1.00K$ -1.11M
Pretax Income
$ -21.32M$ -12.47M$ -13.97M$ -15.28M$ -29.68M$ -21.31M
Tax Provision
-$ -3.42M--$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -21.32M$ -12.47M$ -13.97M$ -15.28M$ -29.68M$ -21.31M
Basic EPS
$ -3.91$ -2.46$ -43.44$ -0.66$ -1.83$ -4.08
Diluted EPS
$ -3.91$ -2.46$ -43.44$ -0.66$ -1.83$ -4.08
Basic Average Shares
$ 56.07M$ 5.07M$ 321.70K$ 23.14M$ 16.22M$ 5.22M
Diluted Average Shares
$ 56.07M$ 5.07M$ 321.70K$ 23.14M$ 16.22M$ 5.22M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 24.66M$ 15.89M$ 19.63M$ 15.30M$ 29.72M$ 20.18M
Net Income From Continuing And Discontinued Operation
$ -21.29M$ -12.47M$ -13.97M$ -15.28M$ -29.68M$ -21.31M
Normalized Income
$ -10.53M---$ -29.68M$ -20.20M
Interest Expense
------
EBIT
$ -21.80M$ -16.36M$ -11.78M$ -15.28M$ -29.72M$ -20.18M
EBITDA
$ -21.05M$ -16.35M$ -11.75M$ -15.24M$ -29.67M$ -20.16M
Currency in USD

NeuroBo Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis